ORIGINAL PAPERS

   BREAST CANCER

Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer

Alexandru Eniu, Frances M. Palmieri, Edith A. Perez
The Oncologist 2005; 10: 665-685 ; doi:10.1634/theoncologist.10-9-665
[Abstract] [Full Text] [PDF]  

Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis

Deborah K. Armstrong, David Spriggs, Jeremey Levin, Ruth Poulin, Stephen Lane
The Oncologist 2005; 10: 686-694 ; doi:10.1634/theoncologist.10-9-686
[Abstract] [Full Text] [PDF]  

Topotecan as Second-Line Therapy for Ovarian Cancer: Dosage Versus Toxicity

Maurie Markman
The Oncologist 2005; 10: 695-697 ; doi:10.1634/theoncologist.10-9-695
[Abstract] [Full Text] [PDF]  

Topotecan: Weighing in When There Are Many Options

Richard T. Penson, Michael V. Seiden
The Oncologist 2005; 10: 698-700 ; doi:10.1634/theoncologist.10-9-698
[Abstract] [Full Text] [PDF]  

Antibody-Based Therapies for Colorectal Cancer

Ki Young Chung, Leonard B. Saltz
The Oncologist 2005; 10: 701-709 ; doi:10.1634/theoncologist.10-9-701
[Abstract] [Full Text] [PDF]  

Combined Therapy with Weekly Irinotecan, Infusional 5-Fluorouracil and the Selective COX-2 Inhibitor Rofecoxib Is a Safe and Effective Second-Line Treatment in Metastatic Colorectal Cancer

Giampietro Gasparini, Domenico Gattuso, Alessandro Morabito, Raffaele Longo, Francesco Torino, Roberta Sarmiento, Stefano Vitale, Teresa Gamucci, Luigi Mariani
The Oncologist 2005; 10: 710-717 ; doi:10.1634/theoncologist.10-9-710
[Abstract] [Full Text] [PDF]  

Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-2a upon Progression

Jonathan D. Schwartz, Max Sung, Myron Schwartz, Deborah Lehrer, John Mandeli, Leonard Liebes, Alec Goldenberg, Matthew Volm
The Oncologist 2005; 10: 718-727 ; doi:10.1634/theoncologist.10-9-718
[Abstract] [Full Text] [PDF]  

Paclitaxel/Carboplatin/Etoposide Versus Paclitaxel/Topotecan for Extensive-Stage Small Cell Lung Cancer: A Minnie Pearl Cancer Research Network Randomized, Prospective Phase II Trial

F. Anthony Greco, Dana S. Thompson, Lisa H. Morrissey, Joan B. Erland, Howard A. Burris, III, David R. Spigel, Geetha Joseph, Steven W. Corso, Ellen Spremulli, John D. Hainsworth
The Oncologist 2005; 10: 728-733 ; doi:10.1634/theoncologist.10-9-728
[Abstract] [Full Text] [PDF]  

Multifocal Extranodal Non-Hodgkin Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study

Theofanis Economopoulos, Sotirios Papageorgiou, Dimitra Rontogianni, Vassiliki Kaloutsi, George Fountzilas, Constantinos Tsatalas, Nikolaos Pavlidis, Dimitrios Pectasides, Efstathios Papageorgiou, Meletios Dimopoulos
The Oncologist 2005; 10: 734-738 ; doi:10.1634/theoncologist.10-9-734
[Abstract] [Full Text] [PDF]  

Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-2b

Karen E. Hurley, Paul B. Chapman
The Oncologist 2005; 10: 739-742 ; doi:10.1634/theoncologist.10-9-739
[Abstract] [Full Text] [PDF]  

Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey

Peter Barrett-Lee, Carsten Bokemeyer, Pere Gascón, J.W.R. Nortier, Maurice Schneider, Dirk Schrijvers, Simon Van Belle, for the Ecas Advisory Board and Participating Centers
The Oncologist 2005; 10: 743-757 ; doi:10.1634/theoncologist.10-9-743
[Abstract] [Full Text] [PDF]  

The Molecular Perspective: c-Abl Tyrosine Kinase

David S. Goodsell
The Oncologist 2005; 10: 758-759 ; doi:10.1634/theoncologist.10-9-758
[Full Text] [PDF]  

Nimotuzumab: Evidence of Clinical Benefit Without Rash

David G.P. Allan
The Oncologist 2005; 10: 760-761 ; doi:10.1634/theoncologist.10-9-760
[Full Text] [PDF]  

Response to "Effect of Patient Exclusion Criteria on the Efficacy of Erythropoiesis-Stimulating Agents in Patients with Cancer-Related Anemia"

Bertrand Coiffier
The Oncologist 2005; 10: 762-763 ; doi:10.1634/theoncologist.10-9-762
[Full Text] [PDF]  

Response to a Letter to the Editor from Coiffier Regarding "Effect of Patient Exclusion Criteria on the Efficacy of Erythropoiesis-Stimulating Agents in Patients with Cancer-Related Anemia"

Timothy J. Littlewood, Brad Schenkel, Martin Liss
The Oncologist 2005; 10: 764-765 ; doi:10.1634/theoncologist.10-9-764
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.